Tag: Piperazine-derived AMPA modulator

Sunifiram (DM-235; 1-benzoyl-4-propanoylpiperazine; CAS 314728-85-3; molecular formula C14H18N2O2; molecular weight 246.31 g/mol) is a synthetic piperazine-derived nootropic compound first disclosed at the University of Florence in approximately 2000 by the Gualtieri research group as a molecular simplification of unifiram (DM-232), itself a bicyclic diazabicyclononanone derivative of the racetam pharmacophore. Despite frequent categorization in the research-chemical literature as an ampakine or racetam analogue, sunifiram is structurally distinct from both classes: it lacks the pyrrolidone ring system that defines the racetam family and does not directly potentiate AMPA receptor currents in the manner of canonical ampakines such as CX-516 or aniracetam. The compound was identified through a program of systematic structural simplification of the piracetam scaffold, in which opening of the pyrrolidone ring and substitution with an acyl piperazine yielded a series of agents with substantially enhanced antiamnesic potency in the mouse passive avoidance test. Sunifiram prevents scopolamine-induced amnesia in mice at intraperitoneal doses of 0.001 to 0.1 mg/kg and at oral doses of 0.01 to 0.1 mg/kg, placing its molar potency approximately four orders of magnitude greater than piracetam and comparable on a per-weight basis to the most potent nootropic agents in the preclinical literature. The compound additionally reverses amnesia induced by mecamylamine (a nicotinic antagonist), baclofen (a GABA-B agonist), and clonidine (an alpha-2 adrenergic agonist), indicating broad-spectrum antiamnesic activity across multiple neurotransmission systems rather than a single-receptor mechanism. In vitro, sunifiram does not display measurable affinity for any of the major central nervous system receptor classes (glutamate, GABA, serotonin, dopamine, adrenergic, histamine, acetylcholine, or opioid) at concentrations up to 10 micromolar in standard radioligand displacement assays. However, the compound enhances long-term potentiation in mouse hippocampal CA1 slices at nanomolar concentrations (10 to 100 nM) with a bell-shaped dose-response relationship, an effect blocked by 7-chlorokynurenic acid (a glycine-site NMDA receptor antagonist) but not by ifenprodil (a polyamine-site NMDA receptor antagonist). This pharmacological dissection, reported by Bhatt et al. (2013), established the glycine-binding site of the NMDA receptor as the principal locus of sunifiram action, with downstream activation of calcium/calmodulin-dependent protein kinase II (CaMKII) and protein kinase C-alpha (PKC-alpha) mediating the synaptic potentiation and the behavioral antiamnesic effect. In the olfactory bulbectomized (OBX) mouse model of cognitive deficit and depression, Moriguchi et al. (2013) demonstrated that oral sunifiram at 0.01 to 1.0 mg/kg daily for 7 to 12 days significantly improved spatial reference memory (Y-maze) and short-term recognition memory (novel object recognition) and restored hippocampal long-term potentiation, without ameliorating depressive behaviors in the tail suspension test. The dissociation between cognitive and affective endpoints supports a mechanism localized to glutamatergic synaptic plasticity rather than monoaminergic mood regulation. Sunifiram increases the release of acetylcholine from rat cerebral cortex in vitro, an effect shared with unifiram and potentially contributing to the procognitive profile. The compound does not impair motor coordination on the rotarod test, does not modify spontaneous locomotor activity on the Animex apparatus, and does not alter inspection activity on the hole board test at effective antiamnesic doses, indicating a clean behavioral profile at therapeutic-range concentrations. As of the most recent monograph revision, sunifiram has not been subjected to formal toxicology testing in any species, has not entered human clinical trials in any jurisdiction, is not approved for medical use anywhere in the world, and is classified by the United States Food and Drug Administration as an unapproved new drug with unlawful use in dietary supplements, food, or medicine. The compound is sold as a research chemical by multiple vendors at purities typically exceeding 98 percent by HPLC. Research-grade vendor literature suggests human doses of 5 to 10 mg per administration, scaled from rodent allometric conversion, but this dose range has not been validated by human pharmacokinetic or safety data. This monograph reviews the chemistry, synthesis, and structure-activity relationships of sunifiram; the glycine-site NMDA receptor mechanism in molecular and electrophysiological detail; the preclinical pharmacology across multiple amnesia models; the absent pharmacokinetic and clinical record; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five nootropic cognition enhancers against sunifiram on five competency standards.

Unifiram (DM-232) is an experimental nootropic compound of the hexahydropyrrolo[1,2-a]pyrazinone structural class, synthesized in the late 1990s at the University of Florence by the research group led by Fulvio Gualtieri within the Department of Pharmaceutical Sciences. The compound was first disclosed in 2000 and characterized in a series of publications by Ghelardini, Galeotti, Romanelli, and colleagues between 2002 and 2006. Unifiram is approximately 1000-fold more potent than piracetam in the mouse passive avoidance test and the rat Morris water maze, the standard behavioral assays for antiamnesic and procognitive activity in the racetam research tradition. The compound prevents amnesia induced by scopolamine (muscarinic antagonism), mecamylamine (nicotinic antagonism), baclofen (GABA-B agonism), and clonidine (alpha-2 adrenergic agonism) at intraperitoneal doses of 0.001 to 0.1 mg/kg and oral doses of 0.01 to 0.1 mg/kg in mice, with no impairment of motor coordination on the rota rod test at doses up to 10 mg/kg.

The mechanism of action is not fully elucidated, but the available evidence supports AMPA receptor-dependent glutamatergic facilitation as the principal pharmacological activity. Unifiram reverses amnesia induced by the selective AMPA receptor antagonist NBQX, increases the amplitude of field excitatory postsynaptic potentials (fEPSP) in rat hippocampal slices in a concentration-dependent manner, and stimulates acetylcholine release from rat cerebral cortex in vitro. Despite these functional effects, unifiram shows no measurable affinity for any of the principal central nervous system receptors, ion channels, or transporters at concentrations up to 1 micromolar in standard radioligand binding panels, including glutamate (AMPA, NMDA, kainate), GABA, serotonin, dopamine, adrenergic, histamine, muscarinic, nicotinic, and opioid sites. The compound therefore appears to operate through an indirect or allosteric mechanism on AMPA receptor-mediated neurotransmission rather than through direct orthosteric binding.

Sunifiram (DM-235), the molecular simplification of unifiram produced by the same research group, retains comparable potency and shares the AMPA-dependent mechanism. A third analog, sapunifiram (MN-19), has also been characterized with similar activity. The structure-activity relationship program at Florence explored modifications of the piperazine and bicyclic ring systems and identified compounds with amnesing (pro-amnestic) activity of comparable potency to scopolamine, confirming the pharmacological specificity of the cognition-enhancing scaffold.

No human clinical trials of unifiram have been conducted. No formal toxicology studies beyond acute rodent dosing have been published. The compound was never patented, and by approximately 2012 it appeared on commercial websites as a consumer nootropic despite the absence of human safety or efficacy data. The 2015 commentary by Gualtieri in the Journal of Enzyme Inhibition and Medicinal Chemistry characterized the commercial availability of unifiram and sunifiram as an illustration of academic and industrial shortcomings in the translation of early-stage research compounds. The compound is not approved for human use in any jurisdiction. It is not scheduled as a controlled substance in most jurisdictions but is sold as a research chemical. Investigators should obtain analytical confirmation of identity and purity on every lot and should not extrapolate rodent dose-response data to human applications without appropriate pharmacokinetic and safety characterization.